Related Experiment Video
Updated: Jun 23, 2025

Acute Myocardial Infarction in Rats
Published on: February 16, 2011
Propranolol Alleviates Cardiac Injury After Acute Catecholamine Infusion Through p38-MAPK Pathways
Tzu-Hao Liu1, Rebecca Jen-Ling Hsieh2, Hsin-Hung Chen2
1Department of Pediatrics, Zuoying Armed Forces General Hospital, Kaohsiung, Taiwan.
Abstract:
Hypercatecholaminergic conditions are known to cause heart failure and cardiac fibrosis when severe. Although previous investigations have studied the effects of beta-blockade in experimental models of catecholaminergic states, the detailed benefits of beta-blockade in more realistic models of hyper-adrenergic states were less clear. In this study, we examined acute cardiac changes in rats with hyperacute catecholamine-induced heart failure with and without propranolol treatment. Male Sprague-Dawley rats (n = 12) underwent a 6-hour infusion of epinephrine and norepinephrine alone, with an additional propranolol bolus (1 mg/kg) at hour 1 (n = 6). Cardiac tissues were examined after 6 hours. Cardiac immunohistochemistry revealed significantly decreased expression of phosphorylated p-38 (left ventricle, P = 0.021; right ventricle, P = 0.021), with upregulation of reactive oxidative species and other profibrosis proteins, after catecholamine infusion alone. After 1 propranolol 1 mg/kg bolus, the levels of phosphorylated-p38 returned to levels comparable with sham (left ventricle, P = 0.021; right ventricle, P = 0.043), with additional findings including downregulation of the apoptotic pathway and profibrotic proteins. We conclude that catecholamine-induced heart failure exerts damage through the p-38 mitogen-activated protein kinase pathway and demonstrates profibrotic changes mediated by matrix metalloproteinase 9, alpha-smooth muscle actin, and fibroblast growth factor 23. Changes in these pathways attenuated acute catecholamine-induced heart failure after propranolol bolus 1 mg/kg. We conclude that propranolol bolus at 1 mg/kg is able to mediate the effects of catecholamine excess through the p-38 mitogen-activated protein kinase pathway, profibrosis, and extrinsic apoptosis pathway.
Insights
Severe hypercatecholaminergic conditions cause heart failure. Propranolol (1 mg/kg) bolus treatment significantly reduced cardiac damage and fibrosis in rats by modulating the p-38 MAPK pathway.
Area of Science:
- Cardiology
- Pharmacology
- Molecular Biology
Background:
- Hypercatecholaminergic conditions can lead to severe heart failure and cardiac fibrosis.
- Previous research on beta-blockade in catecholaminergic states has limitations in realistic models.
- The precise benefits of beta-blockade in hyper-adrenergic states require further investigation.
Purpose of the Study:
- To investigate the acute cardiac changes in a rat model of catecholamine-induced heart failure.
- To evaluate the efficacy of propranolol treatment in mitigating these cardiac changes.
- To elucidate the molecular pathways involved in catecholamine-induced cardiac damage and the effects of propranolol.
Main Methods:
- Male Sprague-Dawley rats underwent a 6-hour infusion of epinephrine and norepinephrine.
- One group received an additional propranolol (1 mg/kg) bolus at hour 1.
- Cardiac tissues were analyzed after 6 hours using immunohistochemistry.
Main Results:
- Catecholamine infusion alone increased reactive oxidative species and profibrosis proteins, decreasing phosphorylated p-38.
- Propranolol treatment normalized phosphorylated p-38 levels and downregulated apoptotic and profibrotic pathways.
- Key profibrotic mediators including MMP-9, α-SMA, and FGF23 were implicated.
Conclusions:
- Catecholamine-induced heart failure involves the p-38 MAPK pathway, profibrosis, and apoptosis.
- A single propranolol bolus (1 mg/kg) effectively attenuated acute catecholamine-induced cardiac damage.
- Propranolol mitigates catecholamine excess by targeting the p-38 MAPK pathway, profibrosis, and apoptosis.
More Related Videos
Related Concept Videos
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Types of β-Blockers
Heart Failure Drugs: β-Blockers
Antihypertensive Drugs: Action of β1 Blockers

